Literature DB >> 30583890

A population-based cohort study examining the risk of abdominal cancer after endovascular abdominal aortic aneurysm repair.

Sheraz R Markar1, Alberto Vidal-Diez2, Viknesh Sounderajah3, Hugh Mackenzie3, George B Hanna3, Matt Thompson4, Peter Holt4, Jesper Lagergren5, Alan Karthikesalingam6.   

Abstract

OBJECTIVE: Endovascular aneurysm repair (EVAR) has increasingly been used as the primary treatment approach for abdominal aortic aneurysm (AAA). This study examined the hypothesis that EVAR leads to an increased risk of abdominal cancer within the radiation field compared with open AAA repair.
METHODS: The nationwide English Hospital Episode Statistics database was used to identify all patients older than 50 years who received an AAA repair in 2005 to 2013. EVAR and open AAA repair groups were compared for the incidence of postoperative cancer using inverse probability weights and G-computation formula to adjust for selection bias and confounding.
RESULTS: Among 14,150 patients who underwent EVAR and 24,645 patients who underwent open AAA repair, follow-up was up to 7 years. EVAR was associated with an increased risk of postoperative abdominal cancer (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.03-1.27) and all cancers (HR, 1.09; 95% CI, 1.02-1.17). However, there was no difference between the groups in the risk of lung cancer (HR, 1.04; 95% CI, 0.92-1.18) or obesity-related nonabdominal cancer (HR, 1.12; 95% CI, 0.69-1.83). Within the EVAR group, use of computed tomography surveillance was not associated with any increased risk of abdominal cancer (HR, 0.94; 95% CI, 0.71-1.23) or all cancers (HR, 0.97; 95% CI, 0.81-1.17).
CONCLUSIONS: This study suggests an increased risk of abdominal cancer after EVAR compared with open AAA repair. The differential cancer risk should be further explored in alternative national populations, and radiation exposure during EVAR should be measured as a quality metric in the assessment of EVAR centers.
Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aneurysm; Cancer; EVAR; Endovascular; Open; Population

Mesh:

Year:  2018        PMID: 30583890     DOI: 10.1016/j.jvs.2018.09.058

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  7 in total

1.  Abdominal Aortic Aneurysm.

Authors:  Martin Czerny; Friedhelm Beyersdorf
Journal:  Dtsch Arztebl Int       Date:  2020-10-20       Impact factor: 5.594

Review 2.  Endovascular and Open Repair of Abdominal Aortic Aneurysm.

Authors:  Thomas Schmitz-Rixen; Dittmar Böckler; Thomas J Vogl; Reinhart T Grundmann
Journal:  Dtsch Arztebl Int       Date:  2020-10-20       Impact factor: 5.594

3.  Management of Concomitant Abdominal Aortic Aneurysm and Intra-abdominal, Retroperitoneal Malignancy.

Authors:  Vladislav Treska; Jiri Molacek; Bohuslav Certik; Karel Houdek; Petr Hosek; Veronika Soukupova; Christiana Stogerova; Aneta Svejdova
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Long-term outcome and cancer incidence after abdominal aortic aneurysm repair.

Authors:  A Ettengruber; J Epple; Th Schmitz-Rixen; D Böckler; R T Grundmann
Journal:  Langenbecks Arch Surg       Date:  2022-09-12       Impact factor: 2.895

Review 5.  Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.

Authors:  Sachin Malde; Wayne Lam; Zainal Adwin; Hashim Hashim
Journal:  BJUI Compass       Date:  2021-02-03

6.  Single centre experience with Excluder® stent graft; 17-year outcome.

Authors:  Ziga Snoj; Tjasa Tomazin; Vladka Salapura; Dimitrij Kuhelj
Journal:  Radiol Oncol       Date:  2022-04-13       Impact factor: 4.214

7.  Multinational data on cumulative radiation exposure of patients from recurrent radiological procedures: call for action.

Authors:  Marco Brambilla; Jenia Vassileva; Agnieszka Kuchcinska; Madan M Rehani
Journal:  Eur Radiol       Date:  2019-12-02       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.